About the HERA Study

The HERA study is a clinical trial for the investigational drug, RG-012. HERA is a Phase II study designed to evaluate the safety and effectiveness of RG-012 compared to placebo in participants with Alport syndrome.

In the HERA study, approximately 40 male participants with a diagnosis of Alport syndrome will be assigned to receive the investigational drug, RG-012 or placebo. The study treatment will be assigned randomly (like flipping a coin):

  • half of the participants will be assigned to RG-012.
  • half of the participants will be assigned to placebo.

Neither the participant nor the doctor will know what study treatment has been assigned.

Travel and lodging assistance is available as well as in-home visits.

You may be qualified for this study if you:

  • Have been diagnosed with Alport syndrome
  • Have not received a kidney transplant
  • Are currently not on dialysis

To locate your nearest study center, please use the site locator. The study team will contact you to review the study requirements and discuss whether you may be eligible to participate.